Skip to content

Spyre Therapeutics, Inc. SYRE Balance Sheet Statement

FY'25FY'24FY'23FY'22
$85.72M-4.1%$89.42M-52.7%$189.22M+420%$36.42M+114%
$670.81M+30.6%$513.67M+242%$150.38M+621%$20.85M-73.3%
$777.78M+27.8%$608.47M+78.2%$341.53M+449%$62.26M-37.0%
$777.78M+27.8%$608.48M+78.0%$341.86M+381%$71.14M-35.3%
$58.69M+8.6%$54.06M+69.1%$31.98M+118%$14.66M-27.2%
$26.68M-70.6%$90.68M+23.7%$73.29M+252%$20.84M-19.8%
400M+3,076,823%13K+30.0%10K+66.7%6K+20.0%
-$1.13B-16.0%-$972.43M-27.2%-$764.41M-79.6%-$425.62M-24.5%
$715.24M+38.1%$517.8M+181%$184.02M+266%$50.31M-40.1%
$777.78M+27.8%$608.48M+78.0%$341.86M+381%$71.14M-35.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Spyre Therapeutics, Inc.'s total assets?
Spyre Therapeutics, Inc. (SYRE) holds $764.0M in total assets, up 34.1% year over year.
How much cash does Spyre Therapeutics, Inc. have?
Spyre Therapeutics, Inc. holds $97.2M in cash and equivalents.
Can Spyre Therapeutics, Inc. cover its short-term obligations?
Its current ratio is 8.97 — current assets exceed current liabilities.
Where does Spyre Therapeutics, Inc.'s balance sheet data come from?
Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.